| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039337121 |
| P356 | DOI | 10.1186/BCR2098 |
| P932 | PMC publication ID | 2481494 |
| P698 | PubMed publication ID | 18485221 |
| P5875 | ResearchGate publication ID | 5365798 |
| P50 | author | Dave S. Hoon | Q47357507 |
| P2093 | author name string | Eiji Sunami | |
| Myung-Shin Sim | |||
| Sandy L Nguyen | |||
| Armando E Giuliano | |||
| Masaru Shinozaki | |||
| Anh-Thu Vu | |||
| P2860 | cites work | Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression | Q24291194 |
| Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene | Q24305178 | ||
| Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression | Q24316952 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis | Q28131703 | ||
| Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype | Q28271274 | ||
| The role for NES1 serine protease as a novel tumor suppressor | Q28288382 | ||
| Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers | Q28343483 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma | Q34274795 | ||
| Concordance among gene-expression-based predictors for breast cancer | Q34555829 | ||
| Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison | Q35605821 | ||
| Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle | Q35788151 | ||
| Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer | Q35992905 | ||
| Role of the Ras-association domain family 1 tumor suppressor gene in human cancers | Q36113844 | ||
| Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators | Q36307445 | ||
| Epigenetic information and estrogen receptor alpha expression in breast cancer | Q36364262 | ||
| Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations | Q36391473 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| Clinical trials with retinoids for breast cancer chemoprevention | Q36443030 | ||
| The receptor expression pattern in ductal carcinoma in situ predicts recurrence | Q36504065 | ||
| DNA methylation as a therapeutic target in cancer | Q36760984 | ||
| Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung | Q38447859 | ||
| RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression | Q40427754 | ||
| Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer | Q40490715 | ||
| A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability | Q40543835 | ||
| Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. | Q40550191 | ||
| Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry | Q42510173 | ||
| Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas | Q42519640 | ||
| Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype | Q42523034 | ||
| Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. | Q42596171 | ||
| Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas | Q43670890 | ||
| Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. | Q43739406 | ||
| Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups | Q44121727 | ||
| Risk factors for breast cancer according to estrogen and progesterone receptor status | Q44753983 | ||
| Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors | Q45877410 | ||
| Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer | Q46639338 | ||
| Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. | Q46882661 | ||
| Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. | Q47420791 | ||
| Estrogen receptors: role in breast cancer. | Q53595317 | ||
| The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. | Q54115075 | ||
| DNA hypermethylation in breast cancer and its association with clinicopathological features. | Q54652899 | ||
| Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome | Q56994624 | ||
| Epigenetic and genetic alterations ofAPCandCDH1genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability | Q57240014 | ||
| Nutrition and breast cancer | Q57421555 | ||
| Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines | Q68090333 | ||
| Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation | Q73715187 | ||
| Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer | Q74256215 | ||
| Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis | Q79886403 | ||
| Hypermethylation in histologically distinct classes of breast cancer | Q80787663 | ||
| Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status | Q81265275 | ||
| Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis | Q81570140 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | estrogen | Q277954 |
| P304 | page(s) | R46 | |
| P577 | publication date | 2008-05-16 | |
| P1433 | published in | Breast Cancer Research | Q2208481 |
| P1476 | title | Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors | |
| P478 | volume | 10 |
| Q58597281 | A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA |
| Q35989635 | Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma |
| Q39122199 | Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients |
| Q36061986 | Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer |
| Q33689442 | Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination |
| Q26783596 | Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review |
| Q37308097 | DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study |
| Q36583742 | DNA methylation and hormone receptor status in breast cancer |
| Q37620392 | DNA methylation as a biomarker in breast cancer |
| Q42496731 | Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes |
| Q28087759 | Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer |
| Q42367979 | Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer |
| Q27694612 | Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q42931926 | Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer |
| Q34625392 | Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status |
| Q33892868 | Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer |
| Q33848807 | Gene promoter methylation is associated with increased mortality among women with breast cancer |
| Q54936274 | Gestational oral low-dose estradiol-17β induces altered DNA methylation of CDKN2D and PSAT1 in embryos and adult offspring. |
| Q33676758 | Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer |
| Q42266190 | Human parvovirus B19 infection leads to downregulation of thyroid, estrogen, and retinoid hormone receptor expression |
| Q35993199 | Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine |
| Q36925229 | Inherited and acquired alterations in development of breast cancer. |
| Q26782613 | Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential |
| Q61814607 | Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy |
| Q38778540 | Intratumor Heterogeneity in Breast Cancer |
| Q28269080 | Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology |
| Q35958967 | Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. |
| Q54484988 | Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. |
| Q39287409 | Methylation in promoter regions of PITX2 and RASSF1A genes in association with clinicopathological features in breast cancer patients |
| Q54569398 | Methylation status and protein expression of RASSF1A in breast cancer patients. |
| Q34048118 | Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns |
| Q37367387 | PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy |
| Q53449089 | Promoter CpG island hypermethylation during breast cancer progression. |
| Q37429833 | Promoter Hypermethylation in Tumor Suppressing Genes p16 and FHIT and Their Relationship with Estrogen Receptor and Progesterone Receptor Status in Breast Cancer Patients from Northern India |
| Q37006733 | Quantitation of CDH1 promoter methylation in formalin-fixed paraffin-embedded tissues of breast cancer patients using differential high resolution melting analysis |
| Q35008011 | Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors |
| Q37437350 | Quantitative assessment of the association between APC promoter methylation and breast cancer |
| Q36865048 | RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients |
| Q53190494 | RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. |
| Q88013658 | TIMP3 Promoter Methylation Represents an Epigenetic Marker of BRCA1ness Breast Cancer Tumours |
| Q57107038 | The Epigenetics of Triple-Negative and Basal-Like Breast Cancer: Current Knowledge |
| Q37177902 | The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients |
| Q47146956 | Tumor Heterogeneity in Breast Cancer |
| Q37699138 | Unique epigenetic gene profiles define human breast cancers with poor prognosis. |
| Q33570282 | Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis |
Search more.